During yesterday’s Federal Trade Commission public workshop on drug pricing competition, Scott Gottlieb, MD, Commissioner of the FDA, called on drug makers to “end the shenanigans” that delay drug competition in the US marketplace.
During yesterday’s Federal Trade Commission public workshop on drug pricing competition, Scott Gottlieb, MD, Commissioner of the FDA, called on drug makers to “end the shenanigans” that delay drug competition in the US marketplace.
Gottlieb’s comment came at the same time as a statement announcing new FDA draft guidance on streamlining the submission and review process for shared-system risk evaluation and mitigation strategies (REMS) programs. While REMS are designed to protect patient safety by providing such materials as medication guides or package inserts (and requiring activities like provider training and patient counseling in some cases), REMS have come under fire as a way that makers of innovator drugs can stave off competition from generics and biosimilars. Because originator product manufacturers and biosimilar or generic drug developers must agree on a single, shared REMS system, REMS programs can potentially be abused to delay the market entry of cheaper drugs.
“Negotiations to reach agreement on shared system REMS can take extended periods of time. This can block the timely entry of a generic competitor,” said Gottlieb. “I believe branded firms sometimes use these negotiations strategically, as a way to slow generic competitors.”
“[We] need to make sure that REMS programs maintain their role in serving public health and don’t become a tool companies can use to delay or block competition from generic products entering the market,” Gottlieb continued, announcing new FDA draft guidance for industry that describes how applicants can submit drug master files, representing all participating firms, to the agency.
The draft guidance, titled “Use of a Drug Master File for Shared System REMS Submissions,” eliminates the need for each manufacturer involved in a REMS process to submit files individually, eliminates duplicative paperwork for drug makers, and streamlines the forms that the FDA’s reviewers must assess. While the new drug master file system is not mandatory, Gottlieb said that “we strongly encourage” its use.
Under the system, only 1 company will be listed as the holder of the master file, and any submission to the file will be assumed to represent the views of all participating REMS applicants. The master file holder must submit a letter of authorization that allows the FDA to review the information in the file in support of REMS applicants.
Among the materials that should be included in the file are the REMS document and materials, the REMS supporting document, REMS assessments and assessment methodologies, REMS correspondence and history, interim versions of documents, responses to the FDA’s requests for information, and file amendments.
Gottlieb also indicated that the FDA will release more information about the circumstances under which it intends to waive the requirement of a single, shared REMS system, including information about how generic drug developers can request waivers.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
The Subcutaneous Revolution: Zymfentra and the Future of IBD Care With Dr Andres Yarur
December 17th 2023On this episode of Not So Different, Andres Yarur, MD, a researcher and associate professor of medicine at Cedars-Sinai Medical Center, discusses the significance of the FDA approval for Zymfentra, the world's first subcutaneous infliximab product, for patients with inflammatory bowel disease (IBD).
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
April 10th 2024A report from the Biosimilars Council evaluating IQVIA data found that rebate schemes orchestrated by pharmacy benefit managers (PBMs) are costing US patients and payers billions of dollars by suppressing biosimilar adoption.